Our Pipeline

Accelerating the delivery of medicines to patients with unmet need

[image placeholder – do not delete]

We are a global company working to accelerate the development and commercialization of important new treatment options that have the potential to improve patient care and outcomes. The diverse development candidates in our pipeline have one thing in common – they are being developed to address conditions with significant unmet patient need.  We have a team of patient-focused experts in drug development who recognize the critical importance of accelerating the development of our pipeline in order to bring new medicines to patients more quickly.

We are also leveraging our unparalleled DrugOME technology and Digital Innovation platform to develop potentially first- or –best-in-class therapies across multiple indications and to speed delivery of new medicines to patients who need new treatment options.  

Myovant Development

Relugolix

Symptoms of Uterine Fibroids — Combination Therapy

Liberty Study — Data Submitted to EMEA

Advanced Prostate Cancer — Monotherapy

Hero Study — Data Submitted to FDA

Symptoms of Endometriosis — Combination Therapy

Spirit Study — Phase 3

MVT-602

Female Infertility as Part of Assisted Reproduction

Phase 2

Japanese Development

Relugolix

Symptoms of Uterine Fibroids — Monotherapy

Approved

Symptoms of Endometriosis — Monotherapy

Phase 2

Visit the Myovant website for additional information

Vibegron

β3-adrenergic Agonist

EMPOWUR Overactive Bladder — NDA Submitted to FDA

Phase 3

Overactive Bladder in Men with BPH

Courage Study Phase 3

Irritable Bowel Syndrome Associated Pain

Phase 2

URO-902

Gene Therapy for Overactive Bladder

Phase 2

Overactive Bladder

Phase 1

Visit the Urovant website for additional information

T-cell Platform

RVT-802

Congenital Athymia

Pre-Registration

rhAC Platform

RVT-801

Farber Disease

IND Enabling

Visit the Enzyvant website for additional information

Rodatristat Ethyl

Pulminary Arterial Hypertension (PAH)

Phase 2

Idiopathic Pulmonary Fibrosis (IPF)

Phase 1

ALTA-2530

Bronchiolitis Obliterans Syndrome

IND Enabling

Visit the Altavant website for additional information

SPIRO-2101

rAAV

Cystic Fibrosis

Preclinical

SPIRO-2102

LVV

Cystic Fibrosis

Preclinical

SPIRO-2110

rAAV

Cystic Fibrosis

Research

Visit the Spirovant website for additional information